The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

Ozzy Osbourne has announced a final Black Sabbath gig as the band reunites for ‘greatest heavy metal show ever.' ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

ROCK veteran Ozzy Osbourne will play his final EVER show this summer, amid his worsening battle with Parkinson’s disease. The ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...

Harrison Ford looks back on his first Indiana Jones role, his ‘Shrinking’ character — a therapist with Parkinson’s disease — ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...